Pharmacological control of hypertriglyceridemia

Area of Science:

• Cardiology
• Vascular Medicine
• Metabolic Syndrome

Background:

• Hypertriglyceridemia is increasingly recognized as a significant vascular risk factor.
• Elevated triglycerides, particularly with low HDL cholesterol or high LDL/HDL ratio, correlate with increased coronary heart disease (CHD) risk.
• High triglycerides alter lipoprotein structure and function, promoting atherogenesis and potentially leading to coronary thrombosis.

Purpose of the Study:

• To review the role of hypertriglyceridemia as a vascular risk factor.
• To discuss the impact of elevated triglycerides on lipoproteins and clotting.
• To outline current diagnostic criteria and management strategies for hypertriglyceridemia.

Main Methods:

• Review of epidemiological and intervention studies on hypertriglyceridemia and cardiovascular risk.
• Analysis of the effects of high triglycerides on plasma lipoproteins and the coagulation system.
• Examination of recent guidelines for hypertriglyceridemia classification and treatment.

Main Results:

• Epidemiological data confirm a strong association between elevated triglycerides and increased CHD risk.
• Triglyceride-lowering interventions show potential for significant CHD risk reduction.
• Management involves nonpharmacological approaches as first-line therapy, with pharmacotherapy for persistent elevations.

Conclusions:

• Hypertriglyceridemia is a modifiable vascular risk factor.
• Lifestyle modifications (weight loss, diet, exercise, smoking/alcohol cessation) are crucial.
• Pharmacological options include fibric acid derivatives, nicotinic acid, n-3 fatty acids, and metformin.